MA50159A - Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps - Google Patents

Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps

Info

Publication number
MA50159A
MA50159A MA050159A MA50159A MA50159A MA 50159 A MA50159 A MA 50159A MA 050159 A MA050159 A MA 050159A MA 50159 A MA50159 A MA 50159A MA 50159 A MA50159 A MA 50159A
Authority
MA
Morocco
Prior art keywords
antibodies
frames
new stable
variable areas
stable combinations
Prior art date
Application number
MA050159A
Other languages
English (en)
Inventor
Dania Diem
Christian Hess
Sebastian Meyer
David Urech
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA50159A publication Critical patent/MA50159A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050159A 2017-09-20 2018-09-19 Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps MA50159A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17192206.5A EP3459968A1 (fr) 2017-09-20 2017-09-20 Nouvelles combinaisons de structure de domaines variables d'anticorps stables

Publications (1)

Publication Number Publication Date
MA50159A true MA50159A (fr) 2020-07-29

Family

ID=59982265

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050159A MA50159A (fr) 2017-09-20 2018-09-19 Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps

Country Status (8)

Country Link
US (2) US11421035B2 (fr)
EP (2) EP3459968A1 (fr)
JP (2) JP2020535799A (fr)
CN (1) CN111133000A (fr)
AU (1) AU2018335823B2 (fr)
CA (1) CA3073882A1 (fr)
MA (1) MA50159A (fr)
WO (1) WO2019057787A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL243311B (en) * 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr) 2020-05-29 2021-12-01 Numab Therapeutics AG Anticorps multi-spécifique
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
CA3205037A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps se liant a il-31
EP4019546A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps qui se lient à il-31
EP4019090A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps liant il-4r
WO2022136693A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
EP4019547A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour il-4r et il-31
KR20230166075A (ko) 2021-02-02 2023-12-06 누맙 세러퓨틱스 아게 Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
TW202246319A (zh) 2021-02-12 2022-12-01 德商百靈佳殷格翰國際股份有限公司 補體c3抗原結合蛋白
EP4183800A1 (fr) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Nouveaux anticorps neutralisants du sars-cov-2
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
EP4273162A1 (fr) 2022-05-06 2023-11-08 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
AU2023265474A1 (en) 2022-05-06 2024-10-31 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (fr) 2022-08-16 2024-02-22 Iome Bio Nouveaux anticorps anti-rgmb
CN121532211A (zh) 2023-05-19 2026-02-13 努玛治疗有限公司 具有降低的免疫原性的抗体可变结构域及抗体
WO2025133389A1 (fr) 2023-12-22 2025-06-26 Numab Therapeutics AG Domaines de liaison à un anticorps ayant une spécificité pour lilrb2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1997008320A1 (fr) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
WO1998056915A2 (fr) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
EA035459B1 (ru) * 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
WO2008004834A1 (fr) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
WO2010144780A1 (fr) 2009-06-12 2010-12-16 University Of Kansas Compositions et méthodes pour établir et conserver des cellules souches dans un état indifférentié
KR101796689B1 (ko) * 2012-08-22 2017-11-10 재단법인 목암생명과학연구소 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
CA2926153A1 (fr) * 2013-10-25 2015-04-30 Numab Ag Constructions bispecifiques et leur utilisation dans le traitement de diverses maladies
MX395604B (es) 2015-06-15 2025-03-25 Numab Therapeutics AG Formato de anticuerpo multiespecífico heterodimérico.

Also Published As

Publication number Publication date
US20200255533A1 (en) 2020-08-13
US11421035B2 (en) 2022-08-23
AU2018335823A1 (en) 2020-02-27
EP3459968A1 (fr) 2019-03-27
CA3073882A1 (fr) 2019-03-28
CN111133000A (zh) 2020-05-08
US20230242651A1 (en) 2023-08-03
AU2018335823B2 (en) 2025-09-04
EP3684802A1 (fr) 2020-07-29
JP2020535799A (ja) 2020-12-10
WO2019057787A1 (fr) 2019-03-28
JP2023115024A (ja) 2023-08-18

Similar Documents

Publication Publication Date Title
MA50159A (fr) Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps
MA49043A (fr) Formulation stable d'anticorps
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3784707A4 (fr) Compositions de microcapsules de polyurée stables
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3478249A4 (fr) Compositions de microcapsules stables
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
EP3615079C0 (fr) Formulations de cannabinoïdes stables
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3481814A4 (fr) Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3419599A4 (fr) Formulations d'antagonistes d'il-6 et leurs utilisations
MA54052A (fr) Formulation d'anticorps
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
EP3773721A4 (fr) Formulations d'immunoconjugué anti-cd79b stables
EP3621640A4 (fr) Constructions d'anticorps d'acide nucléique optimisées
EP3938077A4 (fr) Analyseur de concentration de point d'intervention
EP3893931A4 (fr) Méthodes d'utilisation d'anticorps anti-trem2
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA54139A (fr) Formulation d'anticorps
EP3867272A4 (fr) Utilisation d'anticorps anti-fam19a5
IL263997A (en) Human-enzyme mediated depletion of cystine
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés